首页 > Biolegend > Biolegend/Recombinant Human B7-H1 PD-L1, CD274-Fc Chimera carrier-free/20 µg/762504

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

Biolegend/Recombinant Human B7-H1 PD-L1, CD274-Fc Chimera carrier-free/20 µg/762504

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

762504

品牌：

Biolegend

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

DescriptionPD-L1 is a type I transmembrane protein of 290 amino acids, and it is a member of the B7 family. Human PD-L1 has 70% amino acid identity to its mouse orthologue. Binding of PD-L1 to its receptor PD-1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. PD-L1 induces IL-10 production in T cells stimulated with low levels of anti-CD3. PD-L1/PD-1 interaction suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Disruption of the PD-L1 gene leads to up-regulated T cell responses and the generation of self-reactive T cells. Antibodies against PD-1 or PD-L1 leads to increased antitumor immunity. PD-L1 has an important role in conferring fetomaternal tolerance in an allogeneic pregnancy model; antibodies against PD-L1 lead to a breakdown in maternal tolerance to the fetus. PD-L1 shares its receptor with PD-L2 (CD273, B7-DC). PD-L2 has a more limited expression than PD-L1, being expressed on activated macrophages and dendritic cells. PD-L1 is expressed in many tumors, and the interaction with its receptor activates signaling pathways that inhibit T-cell activity and therefore the antitumor immune response. Antibodies targeting PD-1 or PD-L1 block the PD-1 pathway and reactivate T cell activity.Product Details

美国BioLegend公司是世界著名的流式抗体生产商之一。BioLegend聚集了一批来自BD PharMingen公司的专业人士，建立了一支具有雄厚技术背景的专业队伍。通过其自身的先天优势，以及与世界知名实验室和研究所的良好合作关系，以最合理的价格为生物医药研究的各个前沿领域提供高质量的抗体、试剂盒及其他相关产品